FDA OTC Head Ganley Talks Third Class, Plan B And Drug Switches
This article was originally published in The Tan Sheet
Executive Summary
This spring, FDA's Division of OTC Drug Products will be elevated to full office status within the Center for Drug Evaluation & Research. OTC Division Director Charles Ganley, MD, sat down with "The Tan Sheet" on Dec. 17 to discuss the ramifications of the organizational change, as well as hot-button issues such as the current Rx-to-OTC switch environment, possible monograph system improvements and advisory committee reviews.
You may also be interested in...
Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins
The FDA Office of Nonprescription Products' capacity to be part of a larger unit was a factor in reorganizing ONP into an office that also includes medical imaging oversight, drug center executive John Jenkins says
Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins
The FDA Office of Nonprescription Products' capacity to be part of a larger unit was a factor in reorganizing ONP into an office that also includes medical imaging oversight, drug center executive John Jenkins says
Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins
The FDA Office of Nonprescription Products' capacity to be part of a larger unit was a factor in reorganizing ONP into an office that also includes medical imaging oversight, drug center executive John Jenkins says